Cochrane: We examined research published up to January 2014 on the effect of rituximab (Mabthera, Rituxan) for people with rheumatoid arthritis. From eight studies evaluating 2720 people with rheumatoid arthritis, we found that rituximab probably:
- improved pain, function and other symptoms;
- reduced disease activity;
- reduced joint damage as seen on the x-ray.